|
KMID : 0357920010350020151
|
|
Korean Journal of Pathology
2001 Volume.35 No. 2 p.151 ~ p.157
|
|
|
Expression of Cyclin D1, Cyclin E, p21Cip1 and p27Kip1 in Chemically Induced Rat Mammary Tumor Treated with Tamoxifen and Transforming Growth Factor-β1
|
|
Jang Suk-Yong
Park Jae-Hum
Cho Mee-Yon
Kim Ki-Kwon
Kim Jung-Ran
|
|
|
Abstract
|
|
|
Background: Tamoxifen (TAM) inhibits the action of estrogen by binding to estrogen receptors, and also has non-estrogen receptor mediated cytostatic activities. Transforming growth factor-β1 (TGF-β1) inhibits the proliferation of many other cell types, such as epithelial, hematopoietic and endothelial cells.
Methods: We investigated the effects of tamoxifen on the growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors and the expression of cyclin D1, cyclin E, p21Cip1, and p27Kip1 by performing immunohistochemistry and Western blot analysis, and studied whether TGF-β1 injection amplified the effects of TAM. When tumor size reached between 10-15 mm in the largest dimension, the rats were divided into 3 groups: DMBA-control group (n=12), DMBA-TAM group (n=14) and DMBATAM plus TGF-β1 group (n=5).
Results: The consecutive administration of TAM markedly decreased the tumor development compared with the DMBA-control group. The DMBA-TAM and DMBA-TAM plus TGF-β1 groups showed decreased expression of bromodexoyuridine, cyclin D1, cyclin E, and p21Cip1 when compared with those of the DMBA-control group. On the other hand, the labeling index of p27Kip1 was higher in the DMBA-TAM plus TGF-β1 group than in the DMBA-control group.
Conclusions: TAM suppresses tumor development, which may be associated with down-expression of cyclin D1 and cyclin E, and overexpression of p27Kip1, and addition of TGF-β1 does not influence tumor development treated by TAM.
|
|
|
KEYWORD
|
|
|
Breast, Neoplasms, Cell cycle, Tamoxifen, Transforming growth factor beta
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|